Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• HER2-positive breast cancer often develops resistance to targeted therapies.
• Cyclin D1/CDK4 pathway activation is implicated in this therapeutic resistance.

Purpose of the Study:

• To investigate the role of cyclin D1/CDK4 in mediating resistance to HER2-targeted therapy.
• To evaluate the efficacy of CDK4/6 inhibitors in overcoming this resistance in HER2-positive breast cancer.

Main Methods:

• Utilized transgenic mouse models, cell line-based functional studies, and clinical specimens.
• Investigated the effects of CDK4/6 inhibition on Rb and TSC2 phosphorylation, mTORC1 activity, and EGFR family kinase signaling.
• Assessed the impact of dual EGFR/HER2 and CDK4/6 inhibition on cellular processes and tumor growth in vivo.

Main Results:

• Cyclin D1/CDK4 were identified as mediators of resistance to HER2-targeted therapy.
• CDK4/6 inhibitors suppressed Rb and TSC2 phosphorylation, attenuating mTORC1 activity and resensitizing tumors to HER2 blockade.
• Dual inhibition led to enhanced G1 arrest and a senescence-like phenotype.
• CDK4/6 inhibitors sensitized patient-derived xenograft tumors and delayed recurrence in a transgenic model.

Conclusions:

• CDK4/6 inhibitors represent a promising strategy to overcome cyclin D1/CDK4-mediated resistance in HER2-positive breast cancer.
• Combined inhibition of HER2 and CDK4/6 pathways offers a potent therapeutic approach with enhanced anti-tumor effects.